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Heart-lung transplantation, originally introduced for Eisenmenger's syndrome,' has been successfully used for the treatment of septic lung disease with one year survival exceeding 70% and good functional results.2 This technique results in the unnecessary placing of a denervated donor heart in a patient with no cardiac dysfunction and who, as a result, is exposed to the risks of accelerated coronary artery disease, the incidence of which can be as high as 12%.' Bilateral sequential lung transplantation (BSLT), with hilar anastomoses, retains the innervated heart and reduces the risks of vagal damage and excessive mediastinal bleeding, and has been successfully used in patients with septic lung disease. Lymphoproliferative disease was seen in one patient. Histological appearances were of high grade non-Hodgkin's lymphoma of B cell type consistent with an Epstein-Barr virus driven lymphoproliferative disorder.
There were 23 episodes of rejection (grade A2 and above) treated in 27 patients within six months of transplantation. Obliterative bronchiolitis was diagnosed by transbronchial biopsy in five patients. There was relentless deterioration in all these patients and death within six months of diagnosis despite treatment.
Airway complications were seen in only two patients; ischaemic stenosis of the intermediate bronchus was successfully treated with serial dilatation and stenting in one, and bronchial dehiscence occurred in another patient who subsequently died.
All survivors showed marked improvement in pulmonary function. 
